Randomized Phase III Study of mFOLFOX7 or CAPOX plus Bevacizumab versus 5-Fluorouracil/Leucovorin or Capecitabine plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer (JCOG1018, RESPECT)

ABSTRACT: Interventions: A: Fluoropyrimidine (5-FU/LVor capecitabine) + bevacizumab B: Fluoropyrimidine (5-FU/LV or capecitabine) + oxaliplatin + bevacizumab Primary outcome(s): Progression-free survival Study Design: Parallel Randomized

DISEASE(S): Metastatic Clorectal Cancer

PROVIDER: 2624268 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR